Drug Profile
Research programme: calcification disease therapies - Nanobac
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Nanobac Pharmaceuticals Inc
- Class
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostatitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostatitis in USA
- 19 Jan 2007 Preclinical trials in Prostatitis in USA (unspecified route)